Table 4 List of the top 100 most cited articles
From: The evolution and future of diabetic kidney disease research: a bibliometric analysis
Number | Year | Author | Title | Journal | CT (ACT) | Subcategory | Topic |
|---|---|---|---|---|---|---|---|
1 | 2001 | Brenner BM, et al | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | N Engl J Med | 4699 (234.95) | CS | RAAS |
2 | 2001 | Parving HH, et al | The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | N Engl J Med | 2229 (111.45) | CS | RAAS |
3 | 2008 | Parving HH, et al | Aliskiren combined with losartan in type 2 diabetes and nephropathy | N Engl J Med | 769 (59.15) | CS | RAAS |
4 | 2003 | Steffes MW, et al | Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy - the Epidemiology of Diabetes Interventions and Complications (EDIC) study | JAMA | 751 (41.72) | ES | Undefined |
5 | 2006 | Susztak K, et al | Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy | Diabetes | 731 (48.73) | MG | OS |
6 | 2000 | Ziyadeh FN, et al | Long-term prevention of renal insufficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice | Proc Natl Acad Sci U S A | 707 (33.67) | MG | TGF-β |
7 | 2004 | de Zeeuw D, et al | Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL | Kidney Int | 676 (39.76) | CS | RAAS |
8 | 2002 | Schrier RW, et al | Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes | Kidney Int | 571 (30.05) | CS | BP |
9 | 2013 | Fried LF, et al. | Combined angiotensin inhibition for the treatment of diabetic nephropathy | Kidney Int | 552 (69.00) | CS | RAAS |
10 | 2004 | de Zeeuw D, et al | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy | Circulation | 544 (32.00) | CS | RAAS |
11 | 2010 | Tervaert TWC, et al | Pathologic classification of diabetic nephropathy | J Am Soc Nephrol | 539 (49.00) | PP | Undefined |
12 | 2008 | Zeisberg EM, et al | Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition | J Am Soc Nephrol | 533 (40.92) | MG | Fibroblast |
13 | 2007 | Kato M, et al | MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors | Proc Natl Acad Sci U S A | 518 (36.93) | MG | MiR |
14 | 2003 | Perkins BA, et al | Regression of microalbuminuria in type 1 diabetes | N Engl J Med | 497 (27.61) | CS | T1DM |
15 | 2011 | Haller H, et al | Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes | N Engl J Med | 494 (49.40) | CS | RAAS |
16 | 2011 | de Boer IH, et al | Temporal trends in the prevalence of diabetic kidney disease in the United States | JAMA | 493 (49.30) | ES | Undefined |
17 | 2010 | de Zeeuw D, et al | Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial | Lancet | 482 (43.82) | CS | RAAS |
18 | 2013 | de Zeeuw D, et al | Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease | N Engl J Med | 476 (59.50) | CS | OS |
19 | 2003 | Wendt TM, et al | RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy | Am J Pathol | 438 (24.33) | MG | AGEs/RAGE |
20 | 2009 | Kato M, Y, et al | TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN | Nat Cell Biol | 427 (35.58) | MG | MiR |
21 | 2001 | Yamamoto Y, et al | Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice | J Clin Invest | 390 (19.50) | MG | AGEs/RAGE |
22 | 2005 | Gorin Y, et al | Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney | J Biol Chem | 382 (23.88) | MG | OS |
23 | 2001 | De Vriese, A, et al | Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes | J Am Soc Nephrol | 361 (18.05) | MG | VEGF |
24 | 2000 | Koya D, et al | Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes | FASEB J | 356 (16.95) | MG | OS |
25 | 2004 | Ichihara A, et al | Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin | J Clin Invest | 352 (20.71) | MG | RAAS |
26 | 2009 | Groop PH, et al | The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes | Diabetes | 348 (29.00) | ES | Undefined |
27 | 2003 | Keane WF, et al | The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study | Kidney Int | 345 (19.17) | CS | RAAS |
28 | 1999 | Cooper ME, et al | Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes | Diabetes | 345 (15.68) | MG | VEGF |
29 | 2015 | Kang HM, et al | Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development | Nat Med | 344 (57.33) | MG | Metabolism |
30 | 2000 | Tanji N, et al | Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease | J Am Soc Nephrol | 343 (16.33) | MG | AGEs/RAGE |
31 | 2004 | Chow F, et al | Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury | Kidney Int | 341 (20.06) | MG | Inflammation |
32 | 2017 | Mann JFE, et al | Liraglutide and renal outcomes in type 2 diabetes | N Engl J Med | 337 (84.00) | CS | GLP-1 |
33 | 2011 | Inoki K, et al | mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice | J Clin Invest | 335 (33.50) | MG | Podocyte |
34 | 2012 | Wang B, et al | Suppression of microRNA-29 expression by TGF-beta 1 promotes collagen expression and renal fibrosis | J Am Soc Nephrol | 329 (36.44) | MG | MiR |
35 | 2003 | Sato A, et al | Effectiveness of aldosterone blockade in patients with diabetic nephropathy | Hypertension | 326 (18.11) | CS | RAAS |
36 | 2013 | Yale JF, et al | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Diabetes Obes Metab | 324 (40.38) | CS | SGLT-2 |
37 | 2011 | Godel M, et al | Role of mTOR in podocyte function and diabetic nephropathy in humans and mice | J Clin Invest | 316 (31.60) | MG | Podocyte |
38 | 2001 | Oldfield MD, et al | Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE) | J Clin Invest | 316 (15.80) | MG | AGEs/RAGE |
39 | 2002 | Onozato ML, et al | Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB | Kidney Int | 314 (16.53) | MG | RAAS |
40 | 1999 | Murphy M, et al | Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells | J Biol Chem | 313 (14.23) | MG | CTGF |
41 | 2003 | Berl T, et al | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy | Ann Intern Med | 306 (17.00) | CS | RAAS |
42 | 2000 | Riser BL, et al | Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis | J Am Soc Nephrol | 305 (14.52) | MG | CTGF |
43 | 2006 | Chow FY, et al | Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice | Kidney Int | 304 (20.27) | MG | Inflammation |
44 | 2004 | Bolton WK, et al | Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy | Am J Nephrol | 302 (17.76) | CS | AGEs/RAGE |
45 | 2011 | Zheng HT, et al | Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy | Diabetes | 302 (30.10) | MG | OS |
46 | 2006 | Parving HH, et al | Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective | Kidney Int | 299 (19.93) | ES | Undefined |
47 | 2001 | Steffes MW, et al | Glomerular cell number in normal subjects and in type 1 diabetic patients | Kidney Int | 289 (14.45) | PP | Undefined |
48 | 2008 | Wang Q, et al | MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy | FASEB J | 288 (22.15) | MG | MiR |
49 | 2006 | Schmid H, et al | Modular activation of nuclear factor-kappa B transcriptional programs in human diabetic nephropathy | Diabetes | 279 (18.60) | MG | TF |
50 | 2010 | Mann JFE, et al | Avosentan for overt diabetic nephropathy | J Am Soc Nephrol | 277 (25.18) | CS | RAAS |
51 | 2002 | Yamagishi S, et al | Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells | J Biol Chem | 275 (14.47) | MG | AGEs/RAGE |
52 | 2003 | Bakris GL, et al | Effects of blood pressure level on progression of diabetic nephropathy - results from the RENAAL study | Arch Intern Med | 274 (15.22) | CS | RAAS |
53 | 2007 | Isermann B, et al | Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis | Nat Med | 266 (19.00) | MG | Inflammation |
54 | 2008 | Niranjan T, et al | The Notch pathway in podocytes plays a role in the development of glomerular disease | Nat Med | 264 (20.23) | MG | Podocyte |
55 | 2007 | Nakagawa T, et al | Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy | J Am Soc Nephrol | 262 (18.71) | MG | OS |
56 | 2003 | Babaei-Jadidi R, et al | Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine | Diabetes | 262 (14.56) | MG | Metabolism |
57 | 2010 | Krupa A, et al | Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy | J Am Soc Nephrol | 259 (23.55) | MG | MiR |
58 | 2005 | Thorn LM, et al | Metabolic syndrome in type 1 diabetes - association with diabetic nephropathy and glycemic control (the FinnDiane study) | Diabetes Care | 259 (16.19) | ES | Undefined |
59 | 2003 | Doublier S, et al | Nephrin expression is reduced in human diabetic nephropathy - evidence for a distinct role for glycated albumin and angiotensin II | Diabetes | 259 (14.39) | MG | Podocyte |
60 | 2009 | Coughlan MT, et al | RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes | J Am Soc Nephrol | 258 (21.50) | MG | AGEs/RAGE |
61 | 2004 | Mezzano S, et al | NF-kappa B activation and overexpression of regulated genes in human diabetic nephropathy | Nephrol Dial Transplant | 256 (15.06) | MG | TF |
62 | 2005 | Atkins RC, et al | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy | Am J Kidney Dis | 252 (15.75) | CS | RAAS |
63 | 2005 | Satoh M, et al | NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy | Am J Physiol Renal Physiol | 251 (15.69) | MG | OS |
64 | 2005 | Pohl MA, et al | Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations | J Am Soc Nephrol | 248 (15.50) | CS | RAAS |
65 | 2013 | Sharma K, et al | Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease | J Am Soc Nephrol | 247 (30.88) | MG | Metabolism |
66 | 2007 | Perkins BA, et al | Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes | J Am Soc Nephrol | 247 (17.64) | CS | T1DM |
67 | 2010 | Sedeek M, et al | Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy | Am J Physiol Renal Physiol | 246 (22.36) | MG | OS |
68 | 2000 | Wada T, et al | Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy | Kidney Int | 246 (11.71) | MG | Inflammation |
69 | 2011 | Woroniecka KI, et al | Transcriptome analysis of human diabetic kidney disease | Diabetes | 242 (24.20) | MG | TF |
70 | 2003 | Kiritoshi S, et al | Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells - potential role in diabetic nephropathy | Diabetes | 240 (13.33) | MG | OS |
71 | 2003 | Tikellis C, et al | Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy | Hypertension | 239 (13.28) | MG | RAAS |
72 | 2012 | Wang WJ, et al | Mitochondrial fission triggered by hyperglycemia Is mediated by ROCK1 activation in podocytes and endothelial cells | Cell Metab | 238 (26.44) | MG | OS |
73 | 2010 | Jiang T, et al | The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy | Diabetes | 238 (21.55) | MG | OS |
74 | 2002 | Flyvbjerg A, et al | Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody | Diabetes | 237 (12.47) | MG | VEGF |
75 | 2007 | Eijkelkamp WBA, et al | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial | J Am Soc Nephrol | 236 (16.86) | CS | RAAS |
76 | 2003 | Young BA, et al | Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans | Diabetes Care | 236 (13.11) | ES | Undefined |
77 | 2008 | Li YJ, et al | Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria | Am J Pathol | 235 (18.08) | MG | Podocyte |
78 | 2011 | Wang B, et al. | MiR-200a prevents renal fibrogenesis through repression of TGF-beta 2 expression | Diabetes | 234 (23.40) | MG | MiR |
79 | 2012 | Niewczas MA, et al | Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes | J Am Soc Nephrol | 233 (25.89) | MG | Inflammation |
80 | 2009 | Mehdi UF, et al | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | J Am Soc Nephrol | 232 (19.33) | CS | RAAS |
81 | 2008 | Thallas-Bonke V, et al | Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway | Diabetes | 232 (17.85) | MG | OS |
82 | 2005 | Jiang T, et al | Diet-induced obesity in C57BL/6 J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway | J Biol Chem | 232 (14.50) | MG | Metabolism |
83 | 2012 | Putta S, et al | Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy | J Am Soc Nephrol | 231 (25.67) | MG | MiR |
84 | 2008 | Feldman DL, et al | Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats | Hypertension | 231 (17.77) | MG | RAAS |
85 | 2006 | Zhao HJ, et al | Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice | J Am Soc Nephrol | 231 (15.40) | MG | OS |
86 | 2005 | Berl T, et al | Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial | J Am Soc Nephrol | 228 (14.25) | CS | RAAS |
87 | 2000 | Nakamura T, et al | Urinary excretion of podocytes in patients with diabetic nephropathy | Nephrol Dial Transplant | 228 (10.86) | MG | Podocyte |
88 | 2011 | Palsamy P, et al | Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling | Biochim Biophys Acta | 227 (22.70) | MG | OS |
89 | 2013 | Dugan LL, et al | AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function | J Clin Invest | 226 (28.25) | MG | OS |
90 | 2003 | Okada S, et al | Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes | Diabetes | 226 (12.56) | MG | Inflammation |
91 | 2005 | Asaba K, et al | Effects of NADPH oxidase inhibitor in diabetic nephropathy | Kidney Int | 225 (14.06) | MG | OS |
92 | 2002 | Forbes JM, et al | Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy | Diabetes | 223 (11.74) | MG | RAAS |
93 | 2015 | Bakris GL, et al | Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial | JAMA | 221 (36.83) | CS | RAAS |
94 | 2002 | Ha HJ, et al | Role of high glucose-induced nuclear factor-kappa B activation in monocyte chemoattractant protein-1 expression by mesangial cells | J Am Soc Nephrol | 221 (11.63) | MG | TF |
95 | 2006 | Ichihara A, et al | Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice | J Am Soc Nephrol | 220 (14.67) | MG | RAAS |
96 | 2014 | Vallon V, et al | SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice | Am J Physiol Renal Physiol | 219 (31.29) | MG | SGLT-2 |
97 | 2008 | Zhang Z, et al | Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase | Proc Natl Acad Sci U S A | 218 (16.77) | MG | RAAS |
98 | 2016 | Afkarian M, et al | Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014 | JAMA | 217 (43.40) | ES | Undefined |
99 | 2013 | Zhong X, et al | MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes | Diabetologia | 217 (27.13) | MG | MiR |
100 | 2011 | Kitada M, et al | Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway | Diabetes | 217 (27.13) | MG | OS |